Compare MSD & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MSD | MDXH |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 149.0M |
| IPO Year | N/A | 2021 |
| Metric | MSD | MDXH |
|---|---|---|
| Price | $6.99 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 106.1K | ★ 175.4K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.91 | $1.36 |
| 52 Week High | $7.94 | $5.33 |
| Indicator | MSD | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 30.23 | 15.34 |
| Support Level | N/A | $1.90 |
| Resistance Level | $7.47 | $2.30 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 16.22 | 5.36 |
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.